ALC
ALCON INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 12 ▼ Josh Gottheimer sold $1,001 - $15,000, last disclosed Apr 9
- May 21 Trial readout: Results Pending: Netarsudil 0.01%/latanoprost 0.005% ophth…
- Jun 20 Trial readout: Results Pending: Netarsudil 0.01%/latanoprost 0.005% ophth…
- Jun 26 David Rostov v. Alcon Research, LLc, et al.
- Aug 5 ▼ Kevin Hern sold $1,001 - $15,000, last disclosed Sep 2
- Aug 10 ▲ Alcon reported Q2 2026 net sales of $2.8 billion, up 8% YoY (7% cons…
- Sep 30 ▲ 3 funds open new positions (13F)
- Oct 7 Barclays initiates
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q3 2026: 33 added (3 new), 31 trimmed or exited.
- AnalystsBULLISH
16 of 22 rate it Buy or better.
- Short sellersSTEADY
Short interest −5.7% to 18.45M shares. 12.6 days to cover, ≈3.7% of shares.
- TrendUPTREND
8% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | DOUBLED | $540.5M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $333.1M |
| BARCLAYS PLC | ADD | $157.8M |
| MARSHALL WACE, LLP | DOUBLED | $142.2M |
| Qube Research & Technologies Ltd | DOUBLED | $107.1M |
| 1832 Asset Management L.P. | TRIM | $66.8M |
| Fiera Capital Corp | TRIM | $66.6M |
| THORNBURG INVESTMENT MANAGEMENT INC | TRIM | $48.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
22 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 12, 2026 | Barclays MAINTAIN | Equal-Weight |
| Nov 12, 2026 | Baird MAINTAIN | Outperform |
| Nov 12, 2026 | Stifel MAINTAIN | Hold |
| Nov 11, 2026 | BTIG REITERATE | Buy |
| Nov 11, 2026 | Needham REITERATE | Buy |
| Nov 2, 2026 | Needham REITERATE | Buy |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
5 filings · 3 bullish · 0 bearish · 1 mixed · 1 neutral- NEUTRAL 6-KNov 10, 2026
Alcon reported Q3 2026 net sales of $2.717B, up 5% YoY, and core diluted EPS of $0.91, up 15% YoY…
Alcon's Q3 results met consensus with steady 5% revenue growth and 15% core EPS growth, while the tightened full-year guidance suggests management sees stable near-term trends. Watch for the impact…
- MIXED INST-CLUSTERNov 6, 2026
Three institutional buyers added $32.7M in ALC positions during Q3, led by Barclays doubling its…
The cluster is dominated by Barclays' large add; the two sellers are small relative to the buyer aggregate. Without insider buying, the signal is mixed. Monitor next quarter's 13F to see if Barclays…
- BULLISH 6-KAug 10, 2026
Alcon reported Q2 2026 net sales of $2.8 billion, up 8% YoY (7% constant currency), driven by…
The headline EPS miss is noise from a non-cash impairment; the core results and raised guidance are the real signal. Traders should focus on the 11% core EPS growth and the raised full-year outlook…
- BULLISH COURT-RULINGJun 26, 2026
The Delaware Court of Chancery granted Alcon's motion to dismiss all six counts of a stockholder…
The dismissal removes a derivative lawsuit that could have challenged Alcon's control of Aurion Biotech. With Alcon now holding ~99% of Aurion, watch for potential consolidation or strategic…
All ALC filing & press-release reports (5)
- 6-K reportNov 10, 2026
- INST-CLUSTER reportNov 6, 2026
- 6-K reportAug 10, 2026
- COURT-RULING reportJun 26, 2026
- COURT-RULING reportJun 26, 2026